Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Please provide your email address to receive an email when new articles are posted on . Patients with atopic dermatitis that were resistant to systemic therapies, including dupilumab, were treated ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 clinical study of its oral drug candidate soquelitinib in atopic ...

Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...

Corvus Pharmaceuticals (CRVS) jumped ~66% in the premarket on Tuesday after the clinical-stage biotech announced plans to initiate a mid-stage trial for its lead asset, soquelitinib, for a skin ...

A new study published in the Journal of the European Academy of Dermatology & Venerology showed that in children with severe ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The current treatment options for atopic ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

High-dose upadacitinib was found to be most effective in improving AD and itch severity, quality of life and AD flares, but was determined to be among the most harmful with regard to adverse events.

Young children with moderate-to-severe atopic dermatitis (AD) are shorter on average than their peers. Researchers hypothesized that sleep deprivation or long-term exposure to topical or systemic ...